Psychopharmacology of ADHD
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program will be awarded 1.0 NAPNAP contact hours, of which 1.0 is pharmacology content/1.0 Psychopharmacology content/1.0 Controlled Substance content.
IMPORTANT: This continuing education activity is offered at a reduced rate to NAPNAP and SDBP Members. You must be logged in using your NAPNAP Username and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity at the Non-Member rate, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any payment information. If you are a current member of SDBP, and you are being asked to purchase this activity at the Non-member rate, please contact the SDBP National Office at 703-556-9222 to request assistance with obtaining the member discount code.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: email@example.com
Copyright 2019 © by National Association of Pediatric Nurse Practitioners (NAPNAP) and Society for Developmental Behavioral Pediatrics (SDBP)
Pediatric-focused advanced practice registered nurses
- Differentiate commonly used psychopharmacologic agents for ADHD treatment by efficacy, side effect profile, pediatric FDA approval, and monitoring needs
- Develop treatment plans for children/adolescents with simple ADHD
- Distinguish side effects of medication used to treat ADHD from evolving/unmasking co-morbid conditions
Dawn Garzon Maaks, PhD, CPNP-PC, PMHS, FAANP, University of Portland School of Nursing
- 1.00 Contact hours